Articles Referencing CPRX

FDA Accepts Merck BLA - Analyst Blog

5/15/2013, 12:30 pm from Zacks.com in Investing, Business, Stocks

Merck ( MRK ) recently announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for its ragweed pollen (ambrosia artemisiifolia)... Read >>

Merck KGaA Posts Higher Y/Y Earnings - Analyst Blog

5/15/2013, 12:24 pm from Zacks.com in Investing, Business, Earnings, Stocks

Merck KGaA ( MKGAF ) reported first quarter 2013 earnings per American Depositary Receipt (ADR) of $2.79, up 28.1% year over year. Revenues for the reported quarter were up 4.4% year... Read >>

Dr. Reddy's Earnings Increase Y/Y - Analyst Blog

5/15/2013, 12:23 pm from Zacks.com in Investing, Business, Earnings, Stocks

Dr. Reddy's Laboratories ( RDY ) reported fourth quarter fiscal 2013 earnings per American Depositary Share (ADS) of 60 cents above the year-ago earnings of 40 cents per ADS. The company... Read >>

Forest-Trevena Ink Deal - Analyst Blog

5/14/2013, 12:06 pm from Zacks.com in Investing, Business, Stocks

Forest Laboratories Inc. ( FRX ) recently signed a collaborative licensing option deal with Trevena, Inc. for the latter's mid-stage candidate TRV027. TRV027 is being developed for the... Read >>

Jazz Pharma Posts Higher Y/Y Earnings - Analyst Blog

5/14/2013, 11:02 am from Zacks.com in Investing, Business, Earnings, Stocks

Jazz Pharmaceuticals plc's ( JAZZ ) first quarter 2013 adjusted earnings of 97 cents per share were well above the year-ago earnings of 69 cents per share. Excluding one-time... Read >>

Salix Beats on Earnings - Analyst Blog

5/14/2013, 10:28 am from Zacks.com in Investing, Business, Earnings, Stocks

Salix Pharmaceuticals, Ltd. ( SLXP ) posted first quarter earnings of 56 cents per share, above the Zacks Consensus Estimate of 55 cents and the year-ago earnings of 42 cents. Excluding... Read >>

Narrower-than-Expected Loss at Supernus - Analyst Blog

5/14/2013, 10:21 am from Zacks.com in Investing, Business, Stocks

Supernus Pharmaceuticals, Inc. ( SUPN ) reported first quarter 2013 net loss per share of 60 cents, narrower than the Zacks Consensus Estimate of a loss of 63 cents and the year-ago loss... Read >>

Glaxo/THRX's Breo Ellipta Gets FDA Nod - Analyst Blog

5/13/2013, 6:06 pm from Zacks.com in Investing, Business, Stocks

GlaxoSmithKline ( GSK ) and partner Theravance, Inc. ( THRX ) recently announced that their chronic obstructive pulmonary disease (COPD) candidate, Breo Ellipta has received US Food and... Read >>

Wider-Than-Expected Loss at Anacor - Analyst Blog

5/13/2013, 4:06 pm from Zacks.com in Investing, Business, Stocks

Anacor Pharmaceuticals, Inc. ( ANAC ) reported first quarter 2013 net loss per share of 42 cents, wider than the Zacks Consensus Estimate of a loss of 34 cents but narrower than... Read >>

Pacira Reports Wider Loss - Analyst Blog

5/10/2013, 9:24 am from Zacks.com in Investing, Business, Stocks

Pacira Pharmaceuticals, Inc. ( PCRX ) reported first quarter 2013 net loss per share of 60 cents, wider than the Zacks Consensus Estimate of a loss of 49 cents and the year-ago loss of 47... Read >>

Wider-than-Expected Loss at Avanir - Analyst Blog

5/9/2013, 9:51 am from Zacks.com in Investing, Business, Stocks

Avanir Pharmaceuticals, Inc. ( AVNR ) reported second quarter fiscal 2013 net loss per share of 12 cents, wider than the Zacks Consensus Estimate of a loss of 9 cents, but narrower... Read >>

Ariad Posts Wider Y/Y Loss - Analyst Blog

5/8/2013, 10:23 am from Zacks.com in Investing, Business, Stocks

Ariad Pharmaceuticals, Inc. ( ARIA ) reported first quarter loss of 36 cents per share, wider than the year-ago loss of 25 cents per share but narrower than the Zacks Consensus Estimate of... Read >>

Positive Data on Forest Combo Drug - Analyst Blog

5/7/2013, 4:23 pm from Zacks.com in Investing, Business, Stocks

Forest Laboratories, Inc. ( FRX ) and Almirall, S.A. recently announced positive top-line data on their chronic obstructive pulmonary disease (COPD) fixed dose combination candidate,... Read >>

OncoGenex Loss Lower than Expected - Analyst Blog

5/6/2013, 3:26 pm from Zacks.com in Investing, Business, Stocks

OncoGenex Pharmaceuticals, Inc. ( OGXI ) reported first quarter 2013 net loss per share of 46 cents, narrower than the Zacks Consensus Estimate of a loss of 68 cents and the year-ago loss... Read >>

Wider-than-Expected Loss at Endocyte - Analyst Blog

5/6/2013, 2:18 pm from Zacks.com in Investing, Business, Stocks

Endocyte, Inc. ( ECYT ) reported first quarter 2013 net loss per share of 11 cents, wider than the Zacks Consensus Estimate of a loss of 5 cents but narrower than  the year-ago loss... Read >>